Checkpoint Surgical

Checkpoint Surgical occupies a specialized medical-device niche focused on peripheral nerve surgery rather than broad-based surgical equipment. Its portfolio combines intraoperative nerve stimulation products—including the CHECKPOINT GUARDIAN and CHECKPOINT GEMINI—with surgical instruments such as the CHECKPOINT EDGE Nerve Cutting Kit and biomaterial barriers including the NeuroShield chitosan membrane and ACMShield. This mix spans nerve location and evaluation during procedures as well as protection and repair. The company’s stated focus on working with surgeons and researchers, together with products designed for different steps in nerve care, is a differentiator within its specific clinical focus. Its categories include Health Care and Medical Device, and it has a reported employee range of 51–100. The available company information does not identify distinct, verifiable direct competitors; naming peers or making a company-by-company comparison would therefore be speculative. Its competitive position is best characterized by its focused peripheral-nerve portfolio and combination of stimulation devices, instruments, and biomaterials. The company’s September 2025 first use of investigational Regen10® in the FASTR-TEN trial adds a clinical-development dimension, though it does not by itself establish efficacy, approval, or commercial adoption.

Checkpoint Surgical’s growth has combined staged financing, portfolio expansion, and development of a clinical-stage nerve-regeneration system. Its funding history begins with two Series A rounds in 2009 and 2010, followed by Series B financing in 2012 and 2014, a $7.5 million Series C in 2015, and an $8.8 million Series D in 2018. The company raised $16 million on August 24, 2021, with River Cities Capital identified as lead investor, then added a $4 million Venture Round on June 13, 2024. Across nine rounds, total funding is $48,740,630. The 2021 acquisition of NeuroShield extended the portfolio into chitosan-based nerve protection. Product introductions in 2022—the Checkpoint Edge™ kit and CHECKPOINT GEMINI™ stimulator—broadened its surgical tools. A notable development inflection came on September 5, 2025, with the first use of investigational Regen10® in the FASTR-TEN clinical trial. The company is listed in the 51–100 employee range, and an announced plan to add 18 jobs at its Ohio headquarters signals hiring intent, although no announcement date or roles are specified. These indicators suggest continued development, but do not establish revenue growth or trial outcomes.